LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Bio-Techne Corp

Chiusa

SettoreSettore sanitario

56.24 -0.99

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.8

Massimo

57.23

Metriche Chiave

By Trading Economics

Entrata

-40M

-18M

Vendite

783K

317M

P/E

Media del settore

123.283

35.724

EPS

0.53

Rendimento da dividendi

0.56

Margine di Profitto

-5.577

Dipendenti

3,100

EBITDA

-7.1M

68M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+13.44% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.56%

3.09%

Utili prossimi

29 ott 2025

Prossima data del Dividendo

29 ago 2025

Prossima data del' Ex Dividendo

10 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.6B

8.9B

Apertura precedente

57.23

Chiusura precedente

56.24

Notizie sul Sentiment di mercato

By Acuity

37%

63%

119 / 372 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Bio-Techne Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 ago 2025, 22:51 UTC

Utili

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Utili

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Discorsi di Mercato

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Utili

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Utili

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Utili

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Utili

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Utili

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Utili

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Utili

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Utili

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Utili

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Utili

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Utili

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Utili

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Utili

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Utili

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources FY Underlying Ebitda $527.7 Million

Confronto tra pari

Modifica del prezzo

Bio-Techne Corp Previsione

Obiettivo di Prezzo

By TipRanks

13.44% in crescita

Previsioni per 12 mesi

Media 64.42 USD  13.44%

Alto 75 USD

Basso 53 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bio-Techne Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

11

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

49.67 / 50.24Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

119 / 372 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.